Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study.

ABSTRACT:

Purpose

To evaluate the effect of eculizumab, a systemic inhibitor of complement component (C5), on the growth of geographic atrophy (GA) in patients with age-related macular degeneration (AMD).

Design

Prospective, double-masked, randomized clinical trial.

Participants

Patients with GA measuring from 1.25 to 18 mm(2) based on spectral-domain optical coherence tomography imaging.

Methods

Patients were randomized 2:1 to receive intravenous eculizumab or placebo over 6 months. In the eculizumab treatment arm, the first 10 patients received a low-dose regimen of 600 mg weekly for 4 weeks followed by 900 mg every 2 weeks until week 24, and the next 10 patients received a high-dose regimen of 900 mg weekly for 4 weeks followed by 1200 mg every 2 weeks until week 24.

SUBMITTER: Yehoshua Z 

PROVIDER: S-EPMC4015213 | biostudies-literature | 2014 Mar

REPOSITORIES: biostudies-literature